Investor Presentaiton

Expression relative to benchmark 10 20 30 Antigen (HA) GOD Potency Our new platform enables improved mRNA performance mRNA Sequence Optimization Process Increased Translation Efficiency (Polysome Profiling) 5' cap 5' UTR Coding Region 3' UTR Poly (A) Tail 15 Control sequence - Codon optimized Start Codon Stop Codon Codon 1 Codon 2 Codon 3 Codon 4 Codon 5 Codon 6 AUG GAG CUU CGG AGC UAG ~ 500 000 sequences generated in-silico ~ 1000 Sequences tested in-vitro 30+ Sequences tested in-vivo Source: Data on file 83 Vaccines Investor Event Optimized Construct # mRNA Translationally Active Proportion (%) mRNA copies (%) :༔;:: mRNA Translation ** Control Codon Sequence Optimized ** p < 0.01 Increased Protein Expression (Immunofluorescence) Control Sequence Target Protein Expression 40000- 30000- 20000- 10000- 0 Codon Optimized *** Control Codon Sequence Optimized *** p < 0.001 sanofi

View entire presentation